Atanasiu Doina, Saw Wan Ting, Friedman Harvey M, Cohen Gary H
Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Infectious Disease Division, Department of Medicine, Perelman School of Medicine, Penn Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA 19104, USA.
Viruses. 2025 Feb 12;17(2):249. doi: 10.3390/v17020249.
Herpes simplex viruses (HSV-1 and HSV-2), which can be transmitted both orally and sexually, cause lifelong morbidity and in some cases, meningitis and encephalitis. While both the passive transfer of neutralizing antibodies and placental transfer of anti-HSV monoclonal antibodies (Mabs) have shown therapeutic promise in animal models, clinical trials have yet to identify approved immunotherapeutics for herpes infection. Here, we present strategies for the generation of recombinant bispecific antibodies (BsAbs) that target different domains of glycoprotein D (gD), crucial for HSV entry, that have the potential to outperform the effect of individual Mabs to curb herpes infection. Specifically, we selected three pairs of Mabs from our extensive panel for BsAb design and production based on their binding site and ability to block virus entry. Actual binding of BsAbs to gD and epitope availability on gD after BsAb binding were characterized using surface plasmon resonance (SPR) and inhibition by IgG Fab fragments generated from selected Mabs. While one BsAb exhibited an additive effect similar to that observed using a combination of the Mabs utilized for its generation, two showed antagonistic effects, suggesting that the simultaneous engagement of two epitopes or selective binding to one affected their activity against HSV. One BsAb (DL11/1D3) targeting the binding site for both nectin-1 and HVEM receptors demonstrated synergistic inhibitory activity against HSV, outperforming the effect of the individual antibodies. Recombinant DL11/1D3 antibody variants, in which the size of one or both paratopes was decreased to single chains (scFv-Fc), highlighted differences in potency depending on antibody size and format. We propose that BsAbs to individual glycoproteins offer a potential avenue for herpes therapeutics, but their design, mechanism of action, antibody format, and epitope engagement require careful consideration of structure for optimal efficacy.
单纯疱疹病毒(HSV - 1和HSV - 2)可通过口腔和性传播,会导致终身发病,在某些情况下还会引发脑膜炎和脑炎。虽然中和抗体的被动转移以及抗HSV单克隆抗体(Mab)的胎盘转移在动物模型中均显示出治疗前景,但临床试验尚未确定批准用于疱疹感染的免疫疗法。在此,我们提出了生成重组双特异性抗体(BsAb)的策略,该抗体靶向糖蛋白D(gD)的不同结构域,gD对HSV进入至关重要,这些重组双特异性抗体有可能比单个Mab更有效地抑制疱疹感染。具体而言,我们从大量的Mab库中选择了三对用于BsAb的设计和生产,这是基于它们的结合位点以及阻断病毒进入的能力。使用表面等离子体共振(SPR)以及所选Mab产生的IgG Fab片段的抑制作用,对BsAb与gD的实际结合以及BsAb结合后gD上的表位可用性进行了表征。虽然一种BsAb表现出与使用用于其生成的Mab组合所观察到的相加效应相似,但有两种表现出拮抗作用,这表明同时结合两个表位或选择性结合其中一个会影响它们对HSV的活性。一种靶向nectin - 1和HVEM受体结合位点的BsAb(DL11/1D3)对HSV表现出协同抑制活性,其效果优于单个抗体。重组DL11/1D3抗体变体,其中一个或两个互补决定区的大小减小为单链(scFv - Fc),突出了效力因抗体大小和形式而异。我们提出,针对单个糖蛋白的BsAb为疱疹治疗提供了一条潜在途径,但它们的设计、作用机制、抗体形式和表位结合需要仔细考虑结构以实现最佳疗效。